Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. This is an ASCO Meeting ...

The researchers found that the observed 3-year metastasis-free survival was 87.1 and 85.9% with transdermal estradiol patches and luteinizing hormone-releasing hormone agonists, respectively.

To read this article for CME, click here. May 18, 2007 — A meta-analysis in the May 19 issue of The Lancet shows that luteinizing-hormone-releasing hormone (LHRH) analogues are beneficial in ...

Women who have had early stage breast cancer surgically removed, and whose tumour cells are stimulated by the hormone oestrogen, can benefit from taking Luteinizing hormone releasing hormone (LHRH) ...

Two Sealed Airtight Medical Vials Against Bright Background Front View. Real-world data conflict with a recent meta-analysis including patients from highly selected clinical trial populations.

Differential efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with DNA repair defects: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the ...

or on the link below. Androgen-deprivation therapy (ADT) is a cornerstone in the management of prostate cancer. For many years now, luteinizing hormone-releasing hormone (LHRH) agonists have remained ...

Credit: Getty Images. Real-world data conflict with a recent meta-analysis including patients from highly selected clinical trial populations. Although a recent meta-analysis suggested that ...